gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Corticotropin releasing hormone receptor 1

CRF1, CRH-R1, corticotropin-releasing factor receptor, CRFR1, corticotropin-releasing hormone receptor
This gene encodes a G-protein coupled receptor that binds neuropeptides of the corticotropin releasing hormone family that are major regulators of the hypothalamic-pituitary-adrenal pathway. The encoded protein is essential for the activation of signal transduction pathways that regulate diverse physiological processes including stress, reproduction, immune response and obesity. Alternative splicing results in multiple transcript variants, one of which represents a read-through transcript with the neighboring gene MGC57346. [provided by RefSeq, Jan 2012] (from NCBI)
Top mentioned proteins: CRF2, CRH, V1a, CAN, HAD
Papers on CRF1
Anxiety-like responses induced by nitric oxide within the BNST in mice: Role of CRF1 and NMDA receptors.
New
Nunes-de-Souza et al., São Carlos, Brazil. In Horm Behav, Feb 2016
The role of CRFergic and glutamatergic systems on defensive behavior induced by NOC-9 was investigated with previous intra-BNST infusion of different doses of CP376395, a CRF type 1 receptor antagonist (CRF1), or AP-7, an NMDA (N-methyl-d-aspartate) receptor antagonist.
Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women with 21-Hydroxylase Deficiency.
New
Auchus et al., San Diego, United States. In J Clin Endocrinol Metab, Feb 2016
OBJECTIVES: We evaluated the safety and tolerability of the selective corticotropin releasing factor type 1 (CRF1) receptor antagonist NBI-77860 in women with classic 21OHD and tested the hypothesis that CRF1 receptor blockade decreases early morning ACTH and 17α-hydroxyprogesterone (17OHP) in these patients.
Corticotropin-releasing factor augments LPS-induced immune/inflammatory responses in JAWSII cells.
New
Zhang et al., Hangzhou, China. In Immunol Res, Feb 2016
We investigated the expression of CRF and its receptors CRFR1 and CRFR2 in a colonic DC model (JAWSII cells) in a pro-inflammatory and anti-inflammatory milieu.
Novel developments in genetic and epigenetic mechanisms of anxiety.
Review
New
Domschke et al., Würzburg, Germany. In Curr Opin Psychiatry, Jan 2016
Similar multi-level results have been reported for genetic and epigenetic variation in the OXTR gene, especially in social anxiety disorder (SAD), and for CRHR1 gene variation in women with panic disorder.
Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport.
New
Rissman et al., San Diego, United States. In Plos One, Dec 2015
UNASSIGNED: Stress exposure or increased levels of corticotropin-releasing factor (CRF) induce hippocampal tau phosphorylation (tau-P) in rodent models, a process that is dependent on the type-1 CRF receptor (CRFR1).
Sex differences in the locus coeruleus-norepinephrine system and its regulation by stress.
Review
New
Khantsis et al., Philadelphia, United States. In Brain Res, Dec 2015
Third, we review data revealing how sex differences in the stress receptor, corticotropin releasing factor 1 (CRF1), can increase LC neuronal sensitivity to CRF in females compared to males.
Evidence for the role of corticotropin-releasing factor in major depressive disorder.
Review
New
Summers et al., Fredericksburg, United States. In Neurosci Biobehav Rev, Nov 2015
Recent clinical and preclinical studies, using genetic screening and transgenic rodents, respectively, suggest a major role of the CRF1 gene, and the central expression of CRF1 receptor protein in determining an individual's risk of developing MDD.
Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome.
Review
New
Okumura et al., Asahikawa, Japan. In J Gastroenterol, Aug 2015
CRF in brain and periphery acts through two subtype receptors such as CRF receptor type 1 (CRF1) and type 2 (CRF2), and activating CRF1 exclusively stimulates colonic motor function and induces visceral hypersensitivity.
A Transgenic Rat for Investigating the Anatomy and Function of Corticotrophin Releasing Factor Circuits.
Messing et al., Austin, United States. In Front Neurosci, 2014
The CRF1 receptor antagonist R121919 reduced this Fos induction by two-thirds in these regions.
New Findings on the Neurotransmitter Modulation of Defense in the Dorsal Periaqueductal Gray.
Review
Zangrossi et al., Ribeirão Preto, Brazil. In Cns Neurol Disord Drug Targets, 2014
On the other hand, facilitation of corticotrophin releasing factor- or cholecystokinin-mediated neurotransmission in the DPAG, via CRF1 and CCK2 receptors, respectively, causes panicogenic-like effects with implications for the pathogenesis of PD.
Structure of class B GPCR corticotropin-releasing factor receptor 1.
Impact
Marshall et al., Welwyn Garden City, United Kingdom. In Nature, 2013
The corticotropin-releasing factor receptor type 1 is a class B receptor which mediates the response to stress and has been considered a drug target for depression and anxiety.
Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive.
Impact
Phillips et al., Seattle, United States. In Nature, 2012
Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in response to acute stressors and other arousing environmental stimuli, acts in the nucleus accumbens of naive mice to increase dopamine release through coactivation of the receptors CRFR1 and CRFR2.
Depression and anxiety symptoms among women who carry the FMR1 premutation: impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphisms.
GeneRIF
Sherman et al., Atlanta, United States. In Am J Med Genet B Neuropsychiatr Genet, 2012
Genetic variants in CRHR1 that associate with differential cortisol activation may also modulate levels of anxiety related to the stress of raising a child with fragile X syndrome among women who carry an FMR1 premutation.
Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population.
GeneRIF
Akiyoshi et al., Ōita, Japan. In Am J Med Genet B Neuropsychiatr Genet, 2012
12 single nucleotide polymorphisms (SNPs) CRHR1 and CRHR2 in major depressive disorder patients (n = 173), panic disorder patients (n = 180), and healthy controls, were investigated.
Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis.
GeneRIF
Theoharides et al., In J Allergy Clin Immunol, 2012
decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis
Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation.
GeneRIF
Sawchenko et al., San Diego, United States. In Proc Natl Acad Sci U S A, 2012
Data show that CRFR1 and CRFR2 double-KO mice did not exhibit repeated stress-induced alterations in tau-P or solubility.
Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing.
GeneRIF
Zubieta et al., Ann Arbor, United States. In J Neurosci, 2012
CRHR1 single nucleotide polymorphism rs110402 moderates neural responses to emotional stimuli, suggesting a potential mechanism of vulnerability for the development of major depressive disorder.
Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome.
Impact
Zoghbi et al., Houston, United States. In Nat Genet, 2012
In MECP2-TG1 animals, reducing the levels of Crh or its receptor, Crhr1, suppressed anxiety-like behavior; in contrast, reducing Oprm1 expression improved abnormal social behavior.
Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1.
Impact
GeneRIF
Deussing et al., München, Germany. In Science, 2011
results define a bidirectional model for the role of CRHR1 in anxiety and suggest that an imbalance between CRHR1-controlled anxiogenic glutamatergic and anxiolytic dopaminergic systems might lead to emotional disorders
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
Impact
Genetic Factors for Osteoporosis (GEFOS) Consortium et al., Rotterdam, Netherlands. In Nat Genet, 2009
(LRP4, ARHGAP1, F2), 11p14.1 (DCDC5), 11p15 (SOX6), 16q24 (FOXL1), 17q21 (HDAC5) and 17q12 (CRHR1).
share on facebooktweetadd +1mail to friends